Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
ATTRACT
About the Trial
The Anti TNF Trial in Rheumatoid Arthritis with Concomitant Therapy randomized patients with active rheumatoid arthritis despite methotrexate to infliximab infusions plus methotrexate or methotrexate alone. Combination therapy reduced signs and symptoms substantially more than methotrexate alone and, uniquely for the time, halted erosive joint damage on X rays. TNF blockade, proven shortly before by Maini and Feldmann groups, validated cytokine targeted therapy in autoimmune disease. Infliximab, approved by 1999 shortly after etanercept, helped open the biologics era: adalimumab and eventually multiple classes targeting TNF, IL 6, B cells, JAK pathways. Remission became a realistic treat to target goal for many patients.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...